Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Use of human albumin in UK fell substantially when systematic review was published
| The first 150 words of the full text of this article appear below. |
EDITOR
After publication of the Cochrane Injuries Group Albumin
Reviewers' systematic review of albumin administration in critically
ill patients1 the Committee on Safety of Medicines convened an expert working party to consider the implications for the
use of albumin in the United Kingdom. To date the committee has not
made any announcement. The results of the review were widely reported
in the medical and lay press,2 and this may have
influenced the use of albumin.
We requested data on the monthly issues of albumin solutions to regional blood centres and hospitals between 1993 and 1999 from the Bio Products Laboratory (which serves England and Wales) and the Protein Fractionation Centre of the Scottish National Blood Transfusion Service (which serves Scotland and Northern Ireland). Issues were expressed in kg of albumin, reflecting the total albumin content of the various dose units. A three month moving average of albumin issues was calculated.
Read all Rapid Responses